Altered tryptophan and alanine transport in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD): An in vitro study

Behavioral and Brain Functions

Volumn 7, Issue , 2011, Pages

  Johansson, Jessica ^a   Landgren, Magnus ^b   Fernell, Elisabeth ^b,c,d   Vumma, Ravi ^a   Åhlin, Arne ^c   Bjerkenstedt, Lars ^e   Venizelos, Nikolaos ^a  

^a ÖREBRO UNIVERSITY   (Sweden)

^b SKARABORG HOSPITAL   (Sweden)

^c SKARABORG HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Nordic Institute for Advanced Study   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; TRYPTOPHAN; TYROSINE;

ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; CELL MEMBRANE TRANSPORT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN TRANSPORT; RANK SUM TEST; SCHOOL CHILD; SEROTONINERGIC SYSTEM; SKIN BIOPSY; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ALANINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD-BRAIN BARRIER; CELLS, CULTURED; CHILD; FIBROBLASTS; HUMANS; MALE; PROTEIN TRANSPORT; TRYPTOPHAN;

EID: 80053171785     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-7-40     Document Type: Article

References (55)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248. 10.1016/S0140-6736(05)66915-2, 16023516.
2. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948. 10.1176/appi.ajp.164.6.942, 17541055.
3. Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. American family physician 2009, 79:657-665.
4. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS spectrums 2008, 13:977-984.
5. Thapar A, Langley K, Owen MJ, O'Donovan MC. Advances in genetic findings on attention deficit hyperactivity disorder. Psychological medicine 2007, 37:1681-1692.
6. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biological psychiatry 2005, 57:1313-1323. 10.1016/j.biopsych.2004.11.024, 15950004.
7. Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R, Stefansson H, Stefansson K, Magnusson P, Gudmundsson OO, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010, 376:1401-1408. 10.1016/S0140-6736(10)61109-9, 2965350, 20888040.
8. Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. Journal of clinical psychopharmacology 2008, 28:S39-45. 10.1097/JCP.0b013e318174f92a, 18480676.
9. Oades RD. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). Prog Brain Res 2008, 172:543-565.
10. Seo D, Patrick CJ, Kennealy PJ. Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. Aggress Violent Behav 2008, 13:383-395. 10.1016/j.avb.2008.06.003, 2612120, 19802333.
11. Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 1983, 63:484-546.
12. Hyde R, Taylor PM, Hundal HS. Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem J 2003, 373:1-18. 10.1042/BJ20030405, 1223487, 12879880.
13. Pardridge WM. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 1998, 23:635-644. 10.1023/A:1022482604276, 9566601.
14. Pardridge WM, Oldendorf WH. Transport of metabolic substrates through the blood-brain barrier. J Neurochem 1977, 28:5-12. 10.1111/j.1471-4159.1977.tb07702.x, 833603.
15. Vumma R, Wiesel FA, Flyckt L, Bjerkenstedt L, Venizelos N. Functional characterization of tyrosine transport in fibroblast cells from healthy controls. Neurosci Lett 2008, 434:56-60. 10.1016/j.neulet.2008.01.028, 18262359.
16. Mahadik SP, Mukherjee S. Cultured skin fibroblasts as a cell model for investigating schizophrenia. J Psychiatr Res 1996, 30:421-439. 10.1016/S0022-3956(96)00025-8, 9023786.
17. Stahl SM. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol Bull 1985, 21:663-671.
18. Umeki N, Fukasawa Y, Ohtsuki S, Hori S, Watanabe Y, Kohno Y, Terasaki T. mRNA expression and amino acid transport characteristics of cultured human brain microvascular endothelial cells (hBME). Drug Metab Pharmacokinet 2002, 17:367-373. 10.2133/dmpk.17.367, 15618688.
19. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041. 10.1038/nature08797, 2829121, 20107439.
20. Choi TB, Pardridge WM. Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. J Biol Chem 1986, 261:6536-6541.
21. Hawkins RA, O'Kane RL, Simpson IA, Vina JR. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 2006, 136:218S-226S.
22. Ravi V, Jessica J, Tommy L, Nikolaos V. Tryptophan Transport in Human Fibroblast Cells - A Functional Characterization. International Journal of Tryptophan Research 2011, 4:19-27., http://www.la-press.com/tryptophan-transport-in-human-fibroblast-cells-a-functional-characteri-article-a2600
23. Bjerkenstedt L, Farde L, Terenius L, Edman G, Venizelos N, Wiesel FA. Support for limited brain availability of tyrosine in patients with schizophrenia. Int J Neuropsychopharmacol 2006, 9:247-255.
24. Fernell E, Karagiannakis A, Edman G, Bjerkenstedt L, Wiesel FA, Venizelos N. Aberrant amino acid transport in fibroblasts from children with autism. Neurosci Lett 2007, 418:82-86. 10.1016/j.neulet.2007.03.004, 17412511.
25. Flyckt L, Venizelos N, Edman G, Bjerkenstedt L, Hagenfeldt L, Wiesel FA. Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. Arch Gen Psychiatry 2001, 58:953-958. 10.1001/archpsyc.58.10.953, 11576034.
26. Olsson E, Wiesel FA, Bjerkenstedt L, Venizelos N. Tyrosine transport in fibroblasts from healthy volunteers and patients with schizophrenia. Neurosci Lett 2006, 393:211-215. 10.1016/j.neulet.2005.09.070, 16274928.
27. Wiesel FA, Andersson JL, Westerberg G, Wieselgren IM, Bjerkenstedt L, Hagenfeldt L, Langstrom B. Tyrosine transport is regulated differently in patients with schizophrenia. Schizophr Res 1999, 40:37-42. 10.1016/S0920-9964(99)00029-8, 10541005.
28. Wiesel FA, Venizelos N, Bjerkenstedt L, Hagenfeldt L. Tyrosine transport in schizophrenia. Schizophr Res 1994, 13:255-258. 10.1016/0920-9964(94)90050-7, 7841139.
29. Persson ML, Johansson J, Vumma R, Raita J, Bjerkenstedt L, Wiesel FA, Venizelos N. Aberrant amino acid transport in fibroblasts from patients with bipolar disorder. Neurosci Lett 2009, 457:49-52. 10.1016/j.neulet.2009.03.095, 19429160.
30. Ramchand CN, Peet M, Clark AE, Gliddon AE, Hemmings GP. Decreased tyrosine transport in fibroblasts from schizophrenics: implications for membrane pathology. Prostaglandins Leukot Essent Fatty Acids 1996, 55:59-64. 10.1016/S0952-3278(96)90146-5, 8888124.
31. American Psychiatric Association, Diagnostics and Statistical Manual of Mental Disorders (DSM-IV) 1994, Washington DC: American Psychiatric Press, 4.
32. Gazzola GC, Dall'Asta V, Franchi-Gazzola R, White MF. The cluster-tray method for rapid measurement of solute fluxes in adherent cultured cells. Anal Biochem 1981, 115:368-374. 10.1016/0003-2697(81)90019-1, 7304965.
33. Hagenfeldt L, Venizelos N, Bjerkenstedt L, Wiesel FA. Decreased tyrosine transport in fibroblasts from schizophrenic patients. Life Sci 1987, 41:2749-2757. 10.1016/0024-3205(87)90468-1, 3695804.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
35. Feneant-Thibault M, Galera P, Maccario J, Boutron A, Pujol JP, Moatti N. Interleukin-1 beta-induced changes in the kinetic constants of L-proline uptake in human skin fibroblasts. Biochem J 1991, 276(Pt 1):57-62. 1151143, 1903934.
36. Goenner S, Cosson C, Boutron A, Legrand A, Moatti N. Interleukin-1 beta and interleukin-6 stimulate 2-methylaminoisobutyric acid uptake in HepG2 cells. Int J Biochem Cell Biol 1997, 29:667-674. 10.1016/S1357-2725(97)00002-2, 9363644.
37. Le Maire V, Solito E, Russo-Marie F, Hernvann A, Le Marechal H, Ekindjian OG, Aussel C. System A neutral amino acid transporter regulation by interleukin-1beta in human osteoarthritic synovial cells: evidence for involvement of prostaglandin E(2) as a second messenger. J Cell Physiol 2000, 183:65-73. 10.1002/(SICI)1097-4652(200004)183:1<65::AID-JCP8>3.0.CO;2-H, 10699967.
38. Subramanian M, Kuang PP, Wei L, Rishikof DC, Liu H, Goldstein RH. Modulation of amino acid uptake by TGF-beta in lung myofibroblasts. J Cell Biochem 2006, 99:71-78. 10.1002/jcb.20849, 16598748.
39. Thongsong B, Subramanian RK, Ganapathy V, Prasad PD. Inhibition of amino acid transport system a by interleukin-1beta in trophoblasts. J Soc Gynecol Investig 2005, 12:495-503. 10.1016/j.jsgi.2005.06.008, 16202926.
40. Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH, Ganapathy V. Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function. Biochem Biophys Res Commun 1999, 255:283-288. 10.1006/bbrc.1999.0206, 10049700.
41. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
42. Oades RD. Role of the serotonin system in ADHD: treatment implications. Expert Rev Neurother 2007, 7:1357-1374. 10.1586/14737175.7.10.1357, 17939772.
43. Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev 2006, 26:379-395. 10.1016/j.cpr.2006.01.001, 1892795,1892795, 16504359.
44. Malmberg K, Wargelius HL, Lichtenstein P, Oreland L, Larsson JO. ADHD and Disruptive Behavior scores-associations with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents. BMC Psychiatry 2008, 8:28. 10.1186/1471-244X-8-28, 2383890, 18430257.
45. Arnold LE. Treatment alternatives for Attention-Deficit! Hyperactivity Disorder (ADHD). Journal of Attention Disorders 1999, 3:30-48.
46. Felig P. Amino acid metabolism in man. Annu Rev Biochem 1975, 44:933-955. 10.1146/annurev.bi.44.070175.004441, 1094924.
47. Yudkoff M, Nissim I, Daikhin Y, Lin ZP, Nelson D, Pleasure D, Erecinska M. Brain glutamate metabolism: neuronal-astroglial relationships. Dev Neurosci 1993, 15:343-350. 10.1159/000111354, 7805588.
48. Cormier E. Attention deficit/hyperactivity disorder: a review and update. Journal of pediatric nursing 2008, 23:345-357. 10.1016/j.pedn.2008.01.003, 18804015.
49. Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rastam M, Johnson M, Rothenberger A, Niklasson L. Co-existing disorders in ADHD -- implications for diagnosis and intervention. European child & adolescent psychiatry 2004, 13(Suppl 1):I80-92.
50. Dubovsky SL, Murphy J, Christiano J, Lee C. The calcium second messenger system in bipolar disorders: data supporting new research directions. J Neuropsychiatry Clin Neurosci 1992, 4:3-14.
51. Ehrlich BE, Diamond JM. Lithium, membranes, and manic-depressive illness. J Membr Biol 1980, 52:187-200. 10.1007/BF01869189, 6991708.
52. Lachman HM, Papolos DF. Abnormal signal transduction: a hypothetical model for bipolar affective disorder. Life Sci 1989, 45:1413-1426. 10.1016/0024-3205(89)90031-3, 2572951.
53. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998, 30:193-208. 10.1016/S0920-9964(97)00151-5, 9589514.
54. Seymour RL, Ganapathy V, Mellor AL, Munn DH. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol 2006, 80:1320-1327. 10.1189/jlb.1205727, 16997853.
55. Verrey F. System L: heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Arch 2003, 445:529-533.